

**FORM 51-102F3**

**MATERIAL CHANGE REPORT**

**Item 1 - Name and Address of Company:**

Rapid Dose Therapeutics Corp.  
1121 Walkers Line, Unit 3A  
Burlington, ON L7N 2G4

**Item 2 - Date of Material Change:**

January 15, 2025

**Item 3 - News Release:**

The news release attached hereto as Schedule "A" was disseminated over EIN Presswire on January 15, 2025.

**Item 4 - Summary of Material Change:**

On January 15, 2025, Rapid Dose Therapeutics Corp. (the "Corporation") issued 681,815 common shares in settlement of \$150,000 of directors' fees owing to its non-management directors.

**Item 5 - Full Description of Material Change:**

For a full description of the material change, please refer to the press release of the Corporation dated January 15, 2025, attached hereto as Schedule "A".

**Item 6 - Reliance on subsection 7.1(2) of National Instrument 51-102:**

Not applicable.

**Item 7 - Omitted Information:**

Not applicable.

**Item 8 – Executive Officer:**

The name and business number of an executive officer of the Corporation who is knowledgeable about the material change and this report is Mark Upsdell, Chief Executive Officer, 647-200-4709.

**Item 9 - Date of Report:**

January 15, 2025.

**SCHEDULE "A"**

See attached.